{"filing":{"accession_number":"0001193125-26-338480","cik":"0001819133","ticker":"TNGX","company_name":"Tango Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-07-31","primary_document":"d41277d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526338480/d41277d8k.htm"},"events":[{"id":24707,"run_id":22403,"accession_number":"0001193125-26-338480","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Dr. Barbara Weber's employment as Executive Chair ended on August 3, 2026, and she resigned from all officer and board member positions. While the disclosure includes severance and compensation details, the principal disclosed action is her departure from the company and board. The filing emphasizes the termination of employment and resignation from all positions, making this fundamentally an executive departure event.","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":25359,"accession_number":"0001193125-26-338480","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dr. Barbara Weber's employment as Executive Chair ended on August 3, 2026, and she resigned from all officer and board member positions. While the disclosure includes severance and compensation details, the principal disclosed action is her departure from the company and board. The filing emphasizes the termination of employment and resignation from all positions, making this fundamentally an executive departure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:41:50.419385+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25359,"accession_number":"0001193125-26-338480","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dr. Barbara Weber's employment as Executive Chair ended on August 3, 2026, and she resigned from all officer and board member positions. While the disclosure includes severance and compensation details, the principal disclosed action is her departure from the company and board. The filing emphasizes the termination of employment and resignation from all positions, making this fundamentally an executive departure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:41:50.419385+00:00","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-08-06"}]}